Publications

  1. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N, SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59. Epub 2015 May 15.
    View PubMed
  2. Fussner LA, Heimbach JK, Fan C, Dierkhising R, Coss E, Leise MD, Watt KD. Cardiovascular disease after liver transplantation: When, What, and Who Is at Risk. Liver Transpl. 2015 Jul; 21(7):889-96.
    View PubMed
  3. Bhat M, Watt KD. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk? Clin Transplant. 2015 Jul; 29(7):654-63. Epub 2015 Jun 10.
    View PubMed
  4. Fussner LA, Iyer VN, Cartin-Ceba R, Lin G, Watt KD, Krowka MJ. Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival. Liver Transpl. 2015 Jun 16.
    View PubMed
  5. Aqel BA, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, Murphy JL, Ryland K, Keaveny AP, McLemore R, Vargas HE. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology. 2015 Jun 11.
    View PubMed
  6. Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR. Impact of fibrosis progression on clinical outcome in patients treated for post- transplant hepatitis C recurrence. Liver Int. 2015 Jun 09.
    View PubMed
  7. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, Keaveny AP. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015 Jun; 61(6):1880-6. Epub 2015 Apr 27.
    View PubMed
  8. Sarkar M, Watt KD, Terrault N, Berenguer M. Outcomes in liver transplantation: does sex matter? J Hepatol. 2015 Apr; 62(4):946-55. Epub 2014 Nov 27.
    View PubMed
  9. Pestana L, Swain J, Dierkhising R, Kendrick ML, Kamath PS, Watt KD. Bariatric surgery in patients with cirrhosis with and without portal hypertension: a single-center experience. Mayo Clin Proc. 2015 Feb; 90(2):209-15.
    View PubMed
  10. Watt KD. Is 40 the new 30? Transpl Int. 2015 Feb; 28(2):146-7.
    View PubMed
  11. Fussner LA, Charlton MR, Heimbach JK, Fan C, Dierkhising R, Coss E, Watt KD. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int. 2014 Sep; 34(8):1259-66. Epub 2013 Nov 21.
    View PubMed
  12. Watt KD, Fan C, Therneau T, Heimbach JK, Seaberg EC, Charlton MR. Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events. Liver Transpl. 2014 Jul; 20(7):791-7. Epub 2014 May 26.
    View PubMed
  13. Kim DJ, Clark PJ, Heimbach J, Rosen C, Sanchez W, Watt K, Charlton MR. Recurrence of hepatocellular carcinoma: Importance of mRECIST response to chemoembolization and tumor size. Am J Transplant. 2014; 14(6):1383-90.
  14. Duarte-Rojo A, Budhraja V, Veldt BJ, Goldstein DD, Watt KD, Heimbach JK, McHutchison JG, Tillman HL, Poterucha JJ, Charlton MR. Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl. 2013 Dec; 19(12):1311-7.
    View PubMed
  15. Watt KD. Extrahepatic implications of metabolic syndrome. Liver Transpl. 2013 Nov; 19 Suppl 2:S56-61.
    View PubMed
  16. Guichelaar MM, Gawrieh S, Olivier M, Viker K, Krishnan A, Sanderson S, Malinchoc M, Watt KD, Swain JM, Sarr M, Charlton MR. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity (Silver Spring). 2013 Sep; 21(9):1935-41. Epub 2013 May 29.
    View PubMed
  17. Watt KD, Dierkhising R, Fan C, Heimbach JK, Tillman H, Goldstein D, Thompson A, Krishnan A, Charlton MR. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant. 2013 Sep; 13(9):2450-7. Epub 2013 Jul 16.
    View PubMed
  18. Singal AK, Kamath PS, Francisco Ziller N, DiCecco S, Shoreibah M, Kremers W, Charlton MR, Heimbach JK, Watt KD, Shah VH. Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int. 2013 Aug; 26(8):788-94. Epub 2013 Jun 11.
    View PubMed
  19. Heimbach JK, Watt KD, Poterucha JJ, Ziller NF, Cecco SD, Charlton MR, Hay JE, Wiesner RH, Sanchez W, Rosen CB, Swain JM. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013 Feb; 13(2):363-8. Epub 2012 Nov 08.
    View PubMed
  20. Watt KD. Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation. Liver Transpl. 2012 Nov; 18 Suppl 2:S52-8.
    View PubMed
  21. Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl. 2012 Nov; 18(11):1277-89. Epub 2012 Sep 26.
    View PubMed
  22. Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012 Sep; 18(9):1029-36.
    View PubMed
  23. Singh S, Watt KD. Long-term medical management of the liver transplant recipient: what the primary care physician needs to know. Mayo Clin Proc. 2012 Aug; 87(8):779-90. Epub 2012 Jul 03.
    View PubMed
  24. Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchison JG, Poterucha JJ, Vargas-Vorackova F, Charlton MR. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation. 2012 Jul 27; 94(2):197-203.
    View PubMed
  25. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, Tewani S, McCashland TM, Hoteit MA, Shaked A, Saab S, Chi AC, Tien A, Schiano TD. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012 May; 142(5):1132-1139.e1. Epub 2012 Jan 25.
    View PubMed
  26. Laryea MA, Watt KD. Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl. 2012 May; 18(5):514-23.
    View PubMed
  27. Veldt BJ, Duarte-Rojo A, Thompson AJ, Watt KD, Heimbach JK, Tillmann HL, Goldstein DD, McHutchison JG, Charlton MR. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012 Mar; 12(3):737-44. Epub 2012 Feb 02.
    View PubMed
  28. Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 2012 Feb; 32(2):279-86. Epub 2011 Sep 09.
    View PubMed
  29. Weingarten TN, Mantilla CB, Swain JM, Kendrick ML, Oberhansley JM, Burcham RJ, Ribeiro TC, Watt KD, Schroeder DR, Narr BJ, Sprung J. Nonalcoholic steatohepatitis in bariatric patients with a diagnosis of obstructive sleep apnea. Obes Facts. 2012; 5(4):587-96. Epub 2012 Sep 05.
    View PubMed
  30. Watt KD. Metabolic syndrome: is immunosuppression to blame? Liver Transpl. 2011 Nov; 17 Suppl 3:S38-42.
    View PubMed
  31. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011 Oct; 141(4):1249-53. Epub 2011 Jul 02.
    View PubMed
  32. Massoud O, Heimbach J, Viker K, Krishnan A, Poterucha J, Sanchez W, Watt K, Wiesner R, Charlton M. Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transpl. 2011 Jun; 17(6):723-32.
    View PubMed
  33. Ribeireiro T, Swain J, Sarr M, Kendrick M, Que F, Sanderson S, Krishnan A, Viker K, Watt K, Charlton M. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. Obes Surg. 2011 Mar; 21(3):310-5.
    View PubMed
  34. Coss E, Watt KD, Pedersen R, Dierkhising R, Heimbach JK, Charlton MR. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl. 2011 Jan; 17(1):23-31.
    View PubMed
  35. Makol A, Watt KD, Chowdhary VR. Autoimmune hepatitis: a review of current diagnosis and treatment. Hepat Res Treat. 2011; 2011:390916. Epub 2011 May 15.
    View PubMed
  36. Watt KD. Obesity and metabolic complications of liver transplantation. Liver Transpl. 2010 Oct; 16(S2):S65-71.
    View PubMed
  37. Watt KD, Coss E, Pedersen RA, Dierkhising R, Heimbach JK, Charlton MR. Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation. Liver Transpl. 2010 Aug; 16(8):990-8.
    View PubMed
  38. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010 Jul; 53(1):199-206. Epub 2010 Mar 31.
    View PubMed
  39. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010 Jun; 10(6):1420-7. Epub 2010 May 10.
    View PubMed
  40. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010 May; 85(5):451-8. Epub 2010 Mar 31.
    View PubMed
  41. Watt KDS, Chandok N. Safe use of opioids to manage pain in patients with cirrhosis: Reply. Mayo Clin Proc. 2010; 85(10):960.
  42. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009 Dec; 137(6):2010-7. Epub 2009 Sep 18.
    View PubMed
  43. Koehler E, Watt K, Charlton M. Fatty liver and liver transplantation. Clin Liver Dis. 2009 Nov; 13(4):621-30.
    View PubMed
  44. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009 Aug; 9(8):1707-13. Epub 2009 Jun 16.
    View PubMed
  45. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, Heimbach JK, Janssen HL, Charlton MR. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009 Jun; 9(6):1406-13. Epub 2009 May 13.
    View PubMed
  46. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, Rosen CB, Heimbach JK, Charlton MR. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008 Nov; 8(11):2426-33. Epub 2008 Aug 22.
    View PubMed
  47. Nudo CG, Yoshida EM, Bain VG, Marleau D, Wong P, Marotta PJ, Renner E, Watt KD, Deschenes M. Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol. 2008 Oct; 22(10):821-4.
    View PubMed
  48. Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant. 2008 Mar; 8(3):667-72.
    View PubMed
  49. Watt KD, Burak KW, Deschenes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner E, Yoshida EM, Canadian Transplant Hepatology Outcomes Research Network. Survival after liver transplantation for hepatitis C is unchanged over two decades in Canada. Can J Gastroenterol. 2008 Feb; 22(2):153-4.
    View PubMed
  50. McCashland T, Watt K, Lyden E, Adams L, Charlton M, Smith AD, McGuire BM, Biggins SW, Neff G, Burton JR Jr, Vargas H, Donovan J, Trotter J, Faust T. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007 Sep; 13(9):1246-53.
    View PubMed
  51. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, Nashan B, Peltekian KM. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl. 2007 Aug; 13(8):1109-14.
    View PubMed
  52. Watt K, Kives K, Corbin I, Zhang M, Minuk GY. Lack of susceptibility to ischemic necrosis of the remnant liver following partial hepatectomy in the rat. Hepatogastroenterology. 2007 Mar; 54(74):463-5.
    View PubMed
  53. Tulisov A, McMahon BJ, Koch A, Minuk G, Chulanov V, Bruce MG, Uhanova J, Borresen M, Williams J, Osiowy C, Gelvan A, Alexeeva M, Larke B, Watt K. Viral hepatitis in the Arctic. A review from a Circumpolar Workshop on Viral hepatitis, ICCH13. Alaska Med. 2007; 49(2 Suppl):193-203.
    View PubMed
  54. Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, Huang WY, Nashan B, Peltekian K. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl. 2006 Dec; 12(12):1892-5.
    View PubMed
  55. Watt KD. Abnormal liver enzymes 2-3 months after liver transplantation in a patient with hepatitis C: Report of a case. Liver Transpl. 2006 Nov; 12(11 Suppl 2):S29-31.
    View PubMed
  56. Watt KD, Burak K, Deschenes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner EL, Yoshida EM, Canadian Transplant Hepatology Outcomes Research Network. Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol. 2006 Nov; 20(11):725-34.
    View PubMed
  57. Singh H, Watt K, Veitch R, Cantor M, Duerksen DR. Malnutrition is prevalent in hospitalized medical patients: are housestaff identifying the malnourished patient? Nutrition. 2006 Apr; 22(4):350-4. Epub 2006 Feb 02.
    View PubMed
  58. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl. 2006 Jan; 12(1):134-9.
    View PubMed
  59. Watt KD, Menke T, Lyden E, McCashland TM. Mortality while awaiting liver retransplantation: predictability of MELD scores. Transplant Proc. 2005 Jun; 37(5):2172-3.
    View PubMed
  60. Watt KD, McCashland TM. Transplantation in the alcoholic patient. Semin Liver Dis. 2004 Aug; 24(3):249-55.
    View PubMed
  61. Watt K, Uhanova J, Gong Y, Kaita K, Doucette K, Pettigrew N, Minuk GY. Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection. J Viral Hepat. 2004 May; 11(3):251-6.
    View PubMed
  62. Watt JK, Hawkins K, Zhang M, Lipschitz J, Sandha G, Gong Y, Uhanova J, Minuk GY. Transforming growth factor-beta (TGF-beta) protein levels are not elevated in the blood or bile of patients with primary sclerosing cholangitis: a pilot study. Dig Dis Sci. 2004 Jan; 49(1):5-8.
    View PubMed
  63. Belitsky P, Nashan B, Kiberd B, West K, Legare JF, Keough-Ryan T, Watt K. The year in review--2004. Clin Transpl. 2004; 269-301.
    View PubMed
  64. Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl. 2003 Oct; 9(10):1019-24.
    View PubMed
  65. Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol. 2002 Aug; 97(8):2046-50.
    View PubMed